RAM
ARQT icon

Readystate Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Readystate Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,253
Closed -$2.81M – 385
2025
Q2 		$2.81M Buy
200,253
+140,053
+233% +$1.96M 0.09% 137
2025
Q1 		$942K Buy
+60,200
New +$848K 0.03% 389

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Readystate Asset Management's ARQT Position: Q3 2025 in Review

Readystate Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 200,253 shares — an estimated $2.81M sold.

Readystate Asset Management first reported a position in ARQT in Q1 2025 and held it in 2 quarters. The position peaked at $2.81M in Q2 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Readystate Asset Management reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Readystate Asset Management sold 200,253 Arcutis Biotherapeutics shares in Q3 2025, an estimated $2.81M.
  • Readystate Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 2 quarters.
  • Readystate Asset Management's Arcutis Biotherapeutics position peaked at $2.81M in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.